Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 19Breast 3Lymphoid 2Head & Neck 2Gynecologic 2Thoracic 1Sarcoma 1Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 28Head and Neck Neoplasms 16Mouth Neoplasms 13Oropharyngeal Neoplasms 11Salivary Gland Neoplasms 10Melanoma 7Laryngeal Neoplasms 7Thyroid Neoplasms 6Uterine Cervical Neoplasms 5Hypopharyngeal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Carcinoma 5Breast Neoplasms 5Neoplasm Metastasis 4Nasopharyngeal Carcinoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Urinary Bladder Neoplasms 3Tongue Neoplasms 3Stomach Neoplasms 3Precancerous Conditions 3Neoplasms 3Lung Neoplasms 3Leukoplakia, Oral 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Triple Negative Breast Neoplasms 2Skin Neoplasms 2Recurrence 2Rectal Neoplasms 2

Interventions

pembrolizumab 7Cetuximab 5selpercatinib 3cemiplimab 3Trastuzumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Erlotinib Hydrochloride 3Bortezomib 3sargramostim 2motexafin gadolinium 2entinostat 2Specimen Handling 2Radiotherapy 2Oxaliplatin 2Irinotecan 2Fluorodeoxyglucose F18 2Drug Therapy 2Docetaxel 2Biopsy 2ulixertinib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1tipifarnib 1tanespimycin 1spartalizumab 1serabelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × Biopsy × Head & Neck × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡